English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/101936
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorTrapero, Ana-
dc.contributor.authorLlebaria, Amadeu-
dc.identifierdoi: 10.4155/fmc.14.41-
dc.identifierissn: 1756-8919-
dc.identifiere-issn: 1756-8927-
dc.identifier.citationFuture Medicinal Chemistry 6: 975- 977 (2014)-
dc.description.abstractGaucher disease is a progressive lysosomal storage disorder caused by a deficiency in the activity of β-glucocerebrosidase and is characterized by the accumulation of the glycosphingolipid glucosylceramide in the lysosomes of macrophages that leads to dysfunction in multiple organ system. An emerging strategy for the treatment of Gaucher disease is pharmacological chaperone therapy, based on the use of β-glucocerebrosidase inhibitors that are capable of enhancing residual hydrolytic activity at subinhibitory concentrations. In this article, the most common lysosomal storage disorder, Gaucher disease, is introduced and the current therapeutic strategies based on the use of enzyme inhibitors to ameliorate this disease are discussed, with a focus on the efforts being made toward finding and optimizing novel molecules as pharmacological chaperones for Gaucher disease that offer the promise to remedy this malady-
dc.publisherFuture Science-
dc.titleGlucocerebrosidase inhibitors: Future drugs for the treatment of Gaucher disease?-
dc.description.versionPeer Reviewed-
Appears in Collections:(IQAC) Artículos
(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.